The global COVID-19 diagnostics market was valued at USD 30.02 billion in 2024 and is estimated at USD 26.08 billion in 2025, with a projected value of USD 7.26 billion by 2034. The 2025–2034 forecast period reflects a CAGR of -13.3%. The market covers testing solutions for detecting SARS-CoV-2 infection, and North America was the largest market in 2024. Key players include Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, and BioMérieux.

Point-of-Care Testing Drives Decentralized Access

Demand for point-of-care testing reflects the need for rapid and decentralized options, particularly in remote areas and during emergency scenarios. Rapid antigen kits gained popularity because they deliver results within minutes without complex laboratory equipment. According to a World Health Organization report cited on the reference page, more than 60% of COVID-19 diagnostic tests distributed globally by mid-2021 were rapid antigen tests, underscoring their wide adoption.

Antigen-Based Testing and Multiplex Innovation

Antigen-based testing is registering the highest growth rate among test types, driven by its rapid turnaround time and ease of use in point-of-care and at-home settings. These tests have been instrumental in large-scale screening, particularly in resource-constrained regions with limited laboratory infrastructure, and ongoing innovation continues to improve sensitivity and specificity.

A further trend is the shift to multiplex testing, in which a single test detects multiple viruses or infections simultaneously, reducing the need for separate tests. In September 2025, QuidelOrtho added the QUICKVUE Influenza + SARS Test to its portfolio to help clinicians differentiate between COVID-19 and seasonal flu infections.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/covid-19-diagnostics-market

At-Home Testing Kits Empower Self-Testing

Demand for at-home testing kits surged as individuals sought convenient and safe options that reduce exposure risks. These kits, including rapid antigen and molecular tests, allow users to test themselves without visiting healthcare facilities. Data from the US Food and Drug Administration shows that over 20 at-home diagnostic test kits were approved for emergency use by mid-2022. Companies such as Abbott and Quidel have expanded their product lines to include easy-to-use rapid tests suitable for home use. Companies are also leveraging digital platforms to support real-time data sharing and remote testing services, catering to growing demand for convenience and efficiency.

AI-Powered Diagnostic Tools Improve Accuracy

The integration of AI-powered diagnostic tools and cloud-based platforms has transformed the diagnostics landscape. AI analyzes imaging scans, test results, and patient data in real time, reducing the potential for human error and improving laboratory efficiency. A study published in Nature highlighted AI detecting COVID-19 infection from chest X-rays with accuracy exceeding 90%. Machine learning models can detect COVID-19 patterns with high accuracy, even in asymptomatic or early-stage cases, and continuous AI learning helps diagnostic tools adapt to virus mutations and evolving testing requirements. Digital platforms also support remote result sharing, contact tracing, and epidemiological data collection. However, an insufficient number of trained personnel may present market challenges.

Regional Snapshot

North America holds the largest market share, supported by robust healthcare infrastructure and widespread testing initiatives. Europe benefits from coordinated testing strategies across the European Union, while Asia Pacific is witnessing rapid growth owing to high testing demand in densely populated countries such as China and India. Rising popularity of point-of-care testing and at-home diagnostic solutions further contributes to expansion in the region. Competition centers on sensitivity, speed, and cost-effectiveness, and regional players in Asia Pacific are expanding their presence with cost-competitive diagnostic solutions.

Key Players in the COVID-19 Diagnostics Market

•       Abbott Laboratories

•       Roche Diagnostics

•       Thermo Fisher Scientific

•       Siemens Healthineers

•       BioMérieux

•       PerkinElmer

•       Danaher Corporation

•       Quidel Corporation

•       Hologic

•       Becton Dickinson

•       Cepheid

•       Grifols

•       Stryker Corporation

•       Zhejiang Orient Gene Biotech

•       BGI Genomics

Conclusion

The COVID-19 diagnostics market is projected to decline at a CAGR of -13.3% through 2034, yet innovation continues in rapid, accessible, and digitally enabled testing. Companies are focusing on test accuracy, shorter testing times, and wider product availability, supported by partnerships with healthcare providers and regulatory approvals. Suppliers that align their portfolios with decentralized, multi-pathogen, and data-driven needs are best placed to stay competitive.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market